MarketCap
Facebook
X
Telegram
Abiomed Cost of Revenue | ABMD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Abiomed
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 188 M | 162 M | 151 M | 40 M | 30.1 M | 25 M | 19 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 188 M | 19 M | 87.9 M |
Quarterly Cost of Revenue Abiomed
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.9 M | 52.6 M | - | 47.6 M | 43.9 M | 45.2 M | 47.6 M | 41.1 M | 38.7 M | 36 M | 41.1 M | 40 M | 34.9 M | 37.1 M | 40 M | 34 M | 29.8 M | 30.8 M | 34 M | 34 M | 29.8 M | 30.1 M | 25 M | 21.6 M | 21.9 M | 19.3 M | 19 M | 17.3 M | 15.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 52.6 M | 15.1 M | 34.2 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | - | - | $ 162 M |  France |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
91.8 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 78.5 | - | $ 4.28 B |  Britain |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
NanoVibronix
NAOV
|
2.4 M | - | - | $ 1.08 M | USA |
 |
NuVasive
NUVA
|
337 M | - | - | $ 2.07 B | USA |
 |
Natus Medical Incorporated
NTUS
|
197 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |
 |
Acutus Medical
AFIB
|
19.1 M | - | -26.83 % | $ 2.62 M | USA |
 |
Inari Medical
NARI
|
59.1 M | - | - | $ 4.23 B | USA |
 |
Ra Medical Systems
RMED
|
63 K | - | 10.0 % | $ 610 K | USA |
 |
SmileDirectClub
SDC
|
143 M | - | -53.45 % | $ 9.71 M | USA |
 |
Nemaura Medical
NMRD
|
75.3 K | - | -17.8 % | $ 2.74 M | Britain |
 |
Sientra
SIEN
|
49 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
50 M | - | - | $ 1.07 B | USA |
 |
ShockWave Medical
SWAV
|
95.4 M | - | - | $ 12.3 B | USA |
 |
Surgalign Holdings
SRGA
|
41.7 M | - | -32.98 % | $ 1.68 M | USA |
 |
STRATA Skin Sciences
SSKN
|
12.8 M | - | - | $ 6.6 M | USA |
 |
ReWalk Robotics Ltd.
RWLK
|
13.6 M | - | 7.07 % | $ 66.1 M |  Israel |
 |
Zynex
ZYXI
|
39.4 M | - | - | $ 21.1 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
76.9 M | - | 0.28 % | $ 270 M | USA |
 |
ThermoGenesis Holdings
THMO
|
7.51 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
41 K | - | 3.55 % | $ 7.96 M | USA |